Lenvatinib 4mg Tablets: Multi-Kinase Inhibitor for Hepatocellular Carcinoma

中文版本

背景:晚期肝癌的一线靶向需求

在不可切除的肝细胞癌(HCC)一线治疗中,抗血管生成靶向药物占据核心地位.对于不适合局部治疗或已发生远处转移的患者,系统性靶向治疗是延长生存期的关键手段.GIVE LIFE TIME International 供应的 Lenvatinib(E7080)Lenvima 4mg*30 片剂,是覆盖多靶点的酪氨酸激酶抑制剂(TKI),已获批用于 HCC 及分化型甲状腺癌.

原理:多靶点抗血管生成

Lenvatinib 同时抑制血管内皮生长因子受体(VEGFR 1–3),成纤维细胞生长因子受体(FGFR 1–4),血小板衍生生长因子受体(PDGFR α),KIT 及 RET 等多个靶点.通过阻断肿瘤血管生成相关的多条信号通路,限制病灶血供,从而抑制肿瘤生长与进展.

参数例:关键规格证据

• 规格:4mg 薄膜衣片剂,每盒 30 片(E7080 活性成分)
• 体重分层剂量:体重 ≥60kg 推荐 12mg 每日一次；体重 <60kg 推荐 8mg 每日一次
• 适应症:不可切除肝细胞癌一线,放射性碘难治性分化型甲状腺癌
• 包装形态:30 片/盒,4mg 规格便于 <60kg 患者按 8mg(2片)方案灵活拆分

上述参数依据产品说明书及 EMA/FDA 批准的体重分层给药方案整理,确保临床引用可溯源.

步骤:选型与用药参考

1. 确认诊断为不可切除 HCC 或 RAI 难治性 DTC；
2. 测量患者体重,按 ≥60kg / <60kg 选择 12mg 或 8mg 日剂量；
3. 每日一次固定时间口服,可与食物同服；
4. 定期监测血压,肝功能及肾功能,参照说明书管理高血压等常见反应.

总结

Lenvatinib 4mg 片剂以明确的多靶点抗血管生成机制和体重分层给药参数,为肝细胞癌与甲状腺癌患者提供了可量化的靶向治疗选项.GIVE LIFE TIME International 持续提供符合源厂标准的产品供应与跨境物流支持.

常见问题(FAQ)

Q1:为什么 Lenvatinib 要按体重分层给药? A:因为药物暴露量与体重相关,分层剂量可在保证疗效的同时控制不良反应,8mg/12mg 方案经临床试验验证.

Q2:4mg 规格的意义是什么? A:4mg 单片便于 <60kg 患者以 2 片实现 8mg 日剂量,提升给药灵活性.

English Version

Background: First-Line Targeted Need in Advanced HCC

In first-line treatment of unresectable hepatocellular carcinoma (HCC), anti-angiogenic targeted agents play a central role. For patients unsuitable for local therapy or with distant metastasis, systemic targeted therapy is key to prolonging survival. The Lenvatinib (E7080) Lenvima 4mg*30 tablets supplied by GIVE LIFE TIME International are multi-target tyrosine kinase inhibitors (TKI) approved for HCC and differentiated thyroid cancer.

Mechanism: Multi-Target Anti-Angiogenesis

Lenvatinib simultaneously inhibits vascular endothelial growth factor receptors (VEGFR 1–3), fibroblast growth factor receptors (FGFR 1–4), platelet-derived growth factor receptor (PDGFR α), KIT, and RET. By blocking multiple signaling pathways involved in tumor angiogenesis, it restricts lesion blood supply and inhibits tumor growth and progression.

Parameter Evidence

• Strength: 4mg film-coated tablet, 30 tablets per box (E7080 active ingredient)
• Weight-based dosing: Body weight ≥60kg → 12mg once daily; <60kg → 8mg once daily
• Indications: First-line unresectable HCC, radioactive iodine-refractory differentiated thyroid cancer
• Packaging: 30 tablets/box; 4mg strength enables flexible 8mg (2-tablet) dosing for <60kg patients

These parameters follow the product leaflet and EMA/FDA-approved weight-stratified dosing, ensuring traceable clinical citations.

Steps: Selection & Administration Reference

1. Confirm diagnosis of unresectable HCC or RAI-refractory DTC;
2. Measure body weight; select 12mg or 8mg daily dose by ≥60kg / <60kg;
3. Take once daily at a fixed time, with or without food;
4. Monitor blood pressure, liver and renal function; manage hypertension per leaflet.

Summary

Lenvatinib 4mg tablets offer a quantifiable targeted treatment option for HCC and thyroid cancer patients through a defined multi-target anti-angiogenesis mechanism and weight-stratified dosing. GIVE LIFE TIME International continues to provide source-standard product supply with cross-border logistics support.

FAQ

Q1: Why is Lenvatinib dosed by body weight? A: Drug exposure correlates with weight; stratified dosing maintains efficacy while controlling adverse reactions — the 8mg/12mg regimen is clinically validated.

Q2: What is the purpose of the 4mg strength? A: The 4mg tablet lets <60kg patients achieve the 8mg daily dose with 2 tablets, improving dosing flexibility.